Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00055185
Status:
COMPLETED
Last Update Posted:
2008-10-03
First Post:
2003-02-20
Brief Title:
Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients
Sponsor:
Progenics Pharmaceuticals Inc
Organization:
Progenics Pharmaceuticals Inc
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2008-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine any adverse effects of PRO 542 after administration and to determine the anti-HIV effects of PRO 542 in the patient
Detailed Description:
A 2 arm study involving a series of 3 triweekly doses of PRO 542 One arm will involve patients on a stable dose of anti-retroviral therapy and the other arm will consist of patients not receiving anti-retroviral therapy Three patients will be enrolled in each arm followed by a safety evaluation Following the safety evaluation 3 more patients may be enrolled in each arm After the first 12 patients an additional 12 patients may be enrolled pending safety data
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 5R44AI048278-05 | NIH | None | httpsreporternihgovquickSearch5R44AI048278-05 |